SCHEMBL5324291

SCHEMBL5324291

NC(CCn1ccc2ccccc21)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.59
CDK4 P11802 4/20 0.56
CCND1 P24385 4/20 0.56
KMT2A Q03164 1/20 0.55
MAPK1 P28482 3/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C19 P33261 1/20 0.51
HSD17B10 Q99714 1/20 0.50
DRD2 P14416 1/20 0.49
DRD4 P21917 1/20 0.49
DRD3 P35462 1/20 0.49
RAD52 P43351 1/20 0.48
MTNR1A P48039 1/20 0.47
MTNR1B P49286 1/20 0.47
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46
NTSR1 P30989 1/20 0.46
ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8191415 0.84 KMT2A (0.58) LMNACDK4CCND1KMT2AMAPK1
SCHEMBL31344400 0.84 KMT2A (0.58) LMNACDK4CCND1KMT2AMAPK1
SCHEMBL31344395 0.84 KMT2A (0.58) LMNACDK4CCND1KMT2AMAPK1
SCHEMBL45383 0.84 KMT2A (0.58) LMNACDK4CCND1KMT2AMAPK1
SCHEMBL2700471 0.84 KMT2A (0.58) LMNACDK4CCND1KMT2AMAPK1
SCHEMBL2360340 0.76 KMT2A (0.49) LMNACDK4CCND1KMT2AMAPK1
SCHEMBL29684637 0.76 LMNA (0.73) LMNACDK4CCND1KMT2AMAPK1
SCHEMBL526317 0.76 LMNA (0.73) LMNACDK4CCND1KMT2AMAPK1
SCHEMBL5315659 0.75 CDK4 (0.57) LMNACDK4CCND1KMT2AMAPK1
SCHEMBL7349228 0.74 LMNA (1.00) LMNACDK4CCND1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070258899-A1 Diagnostic and therapeutic agents KARYON-CTT LTD (FI) 2007-11-08 US disclosed
WO-2007113385-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS KARYON-CTT LTD (FI) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070258899-A1 Diagnostic and therapeutic agents YBX1, MLX, TPX2 LMNA 3163/4885CDK4 4234/4885CCND1 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.